Tables
TABLE 1 REGION-WISE PHARMACEUTICAL SPENDING ($MILLION) 10
TABLE 2 TOP PHARMA DRUGS BY SALES IN 2017 12
TABLE 3 GLOBAL THROMBOSIS DRUGS MARKET REVENUE BY REGIONS' 2017-2024 ($MILLION) 41
TABLE 4 OTHER PROMINENT VENDORS IN THE THROMBOSIS DRUGS MARKET 48
TABLE 5 ASPEN PHARMACARE HOLDINGS LIMITED: OFFERINGS 49
TABLE 6 ASPEN PHARMACARE HOLDINGS LIMITED: RECENT DEVELOPMENTS 49
TABLE 7 JOHNSON & JOHNSON: OFFERINGS 54
TABLE 8 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 54
TABLE 9 SANOFI S.A.: PRODUCT OFFERINGS 61
TABLE 10 SANOFI S.A.: RECENT DEVELOPMENTS 61
TABLE 11 BOEHRINGER INGELHEIM GMBH: PRODUCT OFFERINGS 67
TABLE 12 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 67
TABLE 13 BAYER AG: PRODUCT OFFERINGS 73
TABLE 14 BAYER AG: RECENT DEVELOPMENTS 73
TABLE 15 BRISTOL-MYERS SQUIBB: OFFERINGS 79
TABLE 16 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENTS 79
TABLE 17 ASTRAZENECA PLC: SNAPSHOT 85
TABLE 18 ASTRAZENECA PLC: RECENT DEVELOPMENTS 85
TABLE 19 PFIZER INC.: SNAPSHOT 87
TABLE 20 PFIZER INC.: RECENT DEVELOPMENTS 87
TABLE 21 BAXTER INTERNATIONAL INC.: SNAPSHOT 89
TABLE 22 BAXTER INTERNATIONAL INC.: RECENT DEVELOPMENTS 89
TABLE 23 DAIICHI SANKYO: SNAPSHOT 91
TABLE 24 DAIICHI SANKYO: RECENT DEVELOPMENTS 91

LIST OF FIGURE

Charts

CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016) 10
CHART 2 PHARMACEUTICAL MOLECULES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS) 11
CHART 3 R&D INVESTMENTS BY TOP 10 COMPANIES 12
CHART 4 PHARMACEUTICAL DRUGS BY SALES' 2017 ($BILLION) 13
CHART 5 RESEARCH METHODOLOGY OF GLOBAL THROMBOSIS DRUGS MARKET 16
CHART 6 GLOBAL THROMBOSIS DRUGS MARKET REVENUE' 2017-2024 ($MILLION) 20
CHART 7 SEGMENTATION OF GLOBAL THROMBOSIS DRUGS MARKET 24
CHART 8 PEST ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET 24
CHART 9 PORTER 5 FORCES ON GLOBAL THROMBOSIS DRUGS MARKET 25
CHART 10 MARKET DYNAMICS: DRO ANALYSIS 27
CHART 11 DRO - IMPACT ANALYSIS OF GLOBAL THROMBOSIS DRUGS MARKET 30
CHART 12 KEY STAKEHOLDERS 31
CHART 13 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY DRUG CLASS SEGMENTATION' 2017 (%) 33
CHART 14 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY DRUG CLASS SEGMENTATION' 2024 (%) 33
CHART 15 GLOBAL FACTOR XA INHIBITORS MARKET FORECAST' 2017-2024 ($MILLION) 34
CHART 16 GLOBAL LOW MOLECULAR WEIGHT HEPARIN MARKET FORECAST' 2017-2024 ($MILLION) 35
CHART 17 GLOBAL P2Y12 PLATELET INHIBITORS MARKET FORECAST' 2017-2024 ($MILLION) 36
CHART 18 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY INDICATION SEGMENTATION' 2017 (%) 38
CHART 19 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY GEOGRAPHICAL SEGMENTATION' 2017 (%) 40
CHART 20 GLOBAL THROMBOSIS DRUGS MARKET SHARE BY GEOGRAPHICAL SEGMENTATION' 2024 (%) 40
CHART 21 THROMBOSIS DRUGS MARKET REVENUE IN NORTH AMERICA' 2017-2024 ($MILLION) 42
CHART 22 THROMBOSIS DRUGS MARKET REVENUE IN EUROPE' 2017-2024 ($MILLION) 43
CHART 23 THROMBOSIS DRUGS MARKET REVENUE IN ASIA PACIFIC' 2017-2024 ($MILLION) 45
CHART 24 THROMBOSIS DRUGS MARKET REVENUE IN REST OF THE WORLD' 2017-2024 ($MILLION) 45
CHART 25 ASPEN PHARMACARE HOLDINGS LIMITED: OVERVIEW SNAPSHOT 49
CHART 26 ASPEN PHARMACARE HOLDINGS LIMITED: BUSINESS UNITS 50
CHART 27 ASPEN PHARMACARE HOLDINGS LIMITED: GEOGRAPHIC PRESENCE 51
CHART 28 ASPEN PHARMACARE HOLDINGS LIMITED: SWOT ANALYSIS 52
CHART 29 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 56
CHART 30 JOHNSON & JOHNSON: BUSINESS UNITS 57
CHART 31 JOHNSON & JOHNSON: GEOGRAPHIC PRESENCE 58
CHART 32 JOHNSON & JOHNSON: SWOT ANALYSIS 60
CHART 33 SANOFI S.A.: OVERVIEW SNAPSHOT 63
CHART 34 SANOFI S.A.: BUSINESS UNITS 64
CHART 35 SANOFI S.A.: GEOGRAPHIC PRESENCE 65
CHART 36 SANOFI S.A.: SWOT ANALYSIS 66
CHART 37 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT 68
CHART 38 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS 69
CHART 39 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE 70
CHART 40 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS 71
CHART 41 BAYER AG: OVERVIEW SNAPSHOT 74
CHART 42 BAYER AG: BUSINESS UNITS 75
CHART 43 BAYER AG: GEOGRAPHIC PRESENCE 76
CHART 44 BAYER AG: SWOT ANALYSIS 77
CHART 45 BRISTOL-MYERS SQUIBB: OVERVIEW SNAPSHOT 81
CHART 46 BRISTOL-MYERS SQUIBB: BUSINESS UNITS 82
CHART 47 BRISTOL-MYERS SQUIBB: GEOGRAPHIC PRESENCE 83
CHART 48 BRISTOL-MYERS SQUIBB: SWOT ANALYSIS 83